New evidence suggests that there are very high rates of diabetic nephropathy remission five years after bariatric surgery.
An anti-fibrotic and anti-inflammatory drug called pirfenidone may help treat diabetic nephropathy, according to a new randomized, double-blind study.
Lower creatinine excretion rate linked to higher all-cause mortality in type 2 diabetes, nephropathy
Minorities more likely to have proteinuric DKD; less likely to have nonproteinuric DKD.
Minorities also are less likely than non-Hispanic whites to have nonproteinuric diabetic kidney disease.
ACE inhibitor plus an angiotensin receptor blocker was not more effective than either drug alone in patients with diabetic nephropathy.
Improved renal and cardiovascular protection observed in patients with type 2 diabetic nephropathy.
Silymarin significantly decreased UACR compared with placebo in patients with diabetic nephropathy.
Patients with type 2 diabetic nephropathy are more likely to progress to end-stage renal disease (ESRD) than die, according to investigators.
ACE inhibitor of ARB use decreased progression risk in patients with macroalbuminuria at baseline.
Podocytes demonstrate a strong reliance on insulin to function properly, according to a study published in Cell Metabolism (2010;12:329-340).
Researchers have found a seasonal variation in urinary albumin-to-creatinine ratio (UACR) in Japanese patients with type 2 diabetes and early nephropathy, with the highest values in winter and the lowest in summer.
The albumin:creatinine ratio in the first urine excreted in the morning is better than 24-hour urinary albumin excretion in determining the risk for renal events in patients with type 2 diabetes and nephropathy, data show.
Patients with diabetic nephropathy should avoid taking high doses of B vitamins to lower homocysteine levels.
Renal disease patients who have persistent proteinuria despite treatment with the highest approved dosage of the angiotensin receptor blocker candesartan may benefit from higher dosages, a Canadian study finds.
SAN FRANCISCO—British researchers have endorsed U.S. guidelines stating that screening diabetic patients for renal disease should involve estimated glomerular filtration rate (eGFR) in addition to testing for albuminuria.
Aliskiren, an oral direct renin inhibitor, may have renoprotective effects that are independent of its BP-lowering effect in patients with type 2 diabetic nephropathy who are receiving the maximal recommended renoprotective treatment and optimal antihypertensive therapy, researchers report.